Antibody therapy for Lassa fever

被引：24

作者：

Cross, Robert W. ^{[1
,2
]}

Hastie, Kathryn M. ^{[3
]}

Mire, Chad E. ^{[1
,2
]}

Robinson, James E. ^{[4
]}

Geisbert, Thomas W. ^{[1
,2
]}

Branco, Luis M. ^{[5
]}

Saphire, Erica Mann ^{[3
]}

Garry, Robert F. ^{[5
,6
]}

机构：

[1] Univ Texas Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA

[2] Univ Texas Med Branch, Galveston Natl Lab, Galveston, TX 77555 USA

[3] La Jolla Inst Immunol, La Jolla, CA 92037 USA

[4] Tulane Univ, Sch Med, Dept Pediat, 1430 Tulane Ave, New Orleans, LA 70112 USA

[5] Zalgen Labs LLC, Germantown, MD 20876 USA

[6] Tulane Univ, Sch Med, Dept Microbiol & Immunol, 1430 Tulane Ave, New Orleans, LA 70112 USA

来源：

CURRENT OPINION IN VIROLOGY | 2019年 / 37卷

基金：

美国国家卫生研究院;

关键词：

RIFT-VALLEY FEVER; HOSPITAL EPIDEMIC; VIRUS-INFECTION; SIERRA-LEONE; WEST-AFRICA; RIBAVIRIN; DISEASE; MONKEYS; LIBERIA; PLASMA;

D O I：

10.1016/j.coviro.2019.07.003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Serum from convalescent Lassa fever patients was previously shown to be ineffective as a source of protective antibodies in some early studies. Subsequently, monoclonal antibodies (MAbs) to the Lassa virus (LASV) glycoprotein produced by memory B cells of West African patients who survived Lassa fever were identified. Development of MAbs as potential Lassa immunotherapeutics was facilitated by structural studies and mutational analyses that identified protective epitopes on the prefusion form of the LASV glycoprotein. Human mAbs were screened for reactivity to different neutralizing epitopes, potency, and broad reactivity against multiple lineages of LASV. MAbs were downselected in a guinea pig model of Lassa fever. A cocktail of three human MAbs designated Arevirumab-3 rescued 100% of Cynomolgus macaques at advanced stages of disease more than a week post-infection. Antibody therapeutics may be further developed in clinical trials in endemic areas potentially offering a key treatment option for Lassa fever.

引用

页码：97 / 104

页数：8

共 70 条

[1] Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever [J].

Abreu-Mota, Tiago ;

Hagen, Katie R. ;

Cooper, Kurt ;

Jahrling, Peter B. ;

Tan, Gene ;

Wirblich, Christoph ;

Johnson, Reed F. ;

Schnell, Matthias J. .

NATURE COMMUNICATIONS, 2018, 9

[2] A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus [J].

Allen, Elizabeth R. ;

Krumm, Stefanie A. ;

Raghwani, Jayna ;

Halldorsson, Steinar ;

Elliott, Angela ;

Graham, Victoria A. ;

Koudriakova, Elina ;

Harlos, Karl ;

Wright, Daniel ;

Warimwe, George M. ;

Brennan, Benjamin ;

Huiskonen, Juha T. ;

Dowall, Stuart D. ;

Elliott, Richard M. ;

Pybus, Oliver G. ;

Burton, Dennis R. ;

Hewson, Roger ;

Doores, Katie J. ;

Bowden, Thomas A. .

CELL REPORTS, 2018, 25 (13) :3750-+

[3] Clinical Sequencing Uncovers Origins and Evolution of Lassa Virus [J].

Andersen, Kristian G. ;

Shapiro, B. Jesse ;

Matranga, Christian B. ;

Sealfon, Rachel ;

Lin, Aaron E. ;

Moses, Lina M. ;

Folarin, Onikepe A. ;

Goba, Augustine ;

Odia, Ikponmwonsa ;

Ehiane, Philomena E. ;

Momoh, Mambu ;

England, Eleina M. ;

Winnicki, Sarah ;

Branco, Luis M. ;

Gire, Stephen K. ;

Phelan, Eric ;

Tariyal, Ridhi ;

Tewhey, Ryan ;

Omoniwa, Omowunmi ;

Fullah, Mohammed ;

Fonnie, Richard ;

Fonnie, Mbalu ;

Kanneh, Lansana ;

Jalloh, Simbirie ;

Gbakie, Michael ;

Saffa, Sidiki ;

Karbo, Kandeh ;

Gladden, Adrianne D. ;

Qu, James ;

Stremlau, Matthew ;

Nekoui, Mahan ;

Finucane, Hilary K. ;

Tabrizi, Shervin ;

Vitti, Joseph J. ;

Birren, Bruce ;

Fitzgerald, Michael ;

McCowan, Caryn ;

Ireland, Andrea ;

Berlin, Aaron M. ;

Bochicchio, James ;

Tazon-Vega, Barbara ;

Lennon, Niall J. ;

Ryan, Elizabeth M. ;

Bjornson, Zach ;

Milner, Danny A., Jr. ;

Lukens, Amanda K. ;

Broodie, Nisha ;

Rowland, Megan ;

Heinrich, Megan ;

Akdag, Marjan .

CELL, 2015, 162 (04) :738-750

[4]

[Anonymous], 2018, List of Blueprint priority diseases

[5] Lassa Fever in Guinea: I. Epidemiology of Human Disease and Clinical Observations [J].

Bausch, Daniel G. ;

Demby, Austin H. ;

Coulibaly, Mamadi ;

Kanu, James ;

Goba, Augustine ;

Bah, Alpha ;

Conde, Nancouma ;

Wurtzel, Heather L. ;

Cavallaro, Kathleen F. ;

Lloyd, Ethleen ;

Baldet, Fatoumata Binta ;

Cisse, Sekou D. ;

Fofona, Djicondet ;

Savane, Ibrahim K. ;

Tolno, Robert Tamba ;

Mahy, Barry ;

Wagoner, Kent D. ;

Ksiazek, Thomas G. ;

Peters, C. J. ;

Rollin, Pierre E. .

VECTOR-BORNE AND ZOONOTIC DISEASES, 2001, 1 (04) :269-+

[6] Short Report: A Historical Look at the First Reported Cases of Lassa Fever: IgG Antibodies 40 Years After Acute Infection [J].

Bond, Nell ;

Schieffelin, John S. ;

Moses, Lina M. ;

Bennett, Andrew J. ;

Bausch, Daniel G. .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2013, 88 (02) :241-244

[7] Emerging trends in Lassa fever: redefining the role of immunoglobulin M and inflammation in diagnosing acute infection [J].

Branco, Luis M. ;

Grove, Jessica N. ;

Boisen, Matt L. ;

Shaffer, Jeffrey G. ;

Goba, Augustine ;

Fullah, Mohammed ;

Momoh, Mambu ;

Grant, Donald S. ;

Garry, Robert F. .

VIROLOGY JOURNAL, 2011, 8

[8] LASSA FEVER, A NEW VIRUS DISEASE OF MAN FROM WEST AFRICA .3. ISOLATION AND CHARACTERIZATION OF VIRUS [J].

BUCKLEY, SM ;

CASALS, J .

AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1970, 19 (04) :680-&

[9] ISOLATION AND ANTIGENIC CHARACTERIZATION OF LASSA VIRUS [J].

BUCKLEY, SM ;

CASALS, J ;

DOWNS, WG .

NATURE, 1970, 227 (5254) :174-&

[10] CEPI: preparing for the worst [J].

Burki, Talha .

LANCET INFECTIOUS DISEASES, 2017, 17 (03) :265-266

← 1 2 3 4 5 6 7 →